Annual General Meeting

The annual general meeting of DiaGenic ASA was held on 23 May 2011.

All proposals set out in the notice to the general meeting were approved.

In accordance with the recommendation from the Nomination Committee Henrik Lund was re-elected as Chairman of the board, and board members Ingrid Wiik and Gustav Ingemar Kihlström were re-elected, and Ulrica Slåne and Tom Pike were elected as new members of the board.

Siri Fürst was re-elected as Chair of the Nomination Committee, and Andreas Lorentzen (Storebrand Kapitalforvaltning) and Leif Eriksrød (Alfred Berg Kapitalforvaltning) were elected as a new members of the Nomination Committee.

The minutes from the annual general meeting will be available at

http://www.newsweb.no and http://www.diagenic.com

Erik Christensen, CEO

Telephone: +47 95939918

e-mail: erik.christensen@diagenic.com

Henrik Lund, Chairman

Telephone: +47 909 71 219

e-mail: henrik.lund@diagenic.com

About DiaGenic ASA

DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer’s Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com